Martin P, Furman RF, Coleman M, Leonard JP. Phase I-III Trials of Anti-B Cell Therapy in Non-Hodgkin's Lymphoma. Clin Cancer Res, 2007;13:5636s-5642 PMID 17875800
Martin P, Leonard JP. Targeted Therapies for Non-Hodgkin's Lymphoma: Rationally Designed Combinations. Clin Lymphoma Myeloma, 2007;7:S192-S198 PMID 17877844
Martin P, Leonard JP. Novel Therapeutic Targets in Mantle Cell Lymphoma. Expert Opin Ther Targets, 2007;11(7):929-940 PMID 17614761
Martin P, Leonard JP. IL-4 as therapy for non-Hodgkin's lymphoma: possibilities but major challenges. Leukemia and Lymphoma, 2007;48(7):1259-1260
Leonard JP, Ruan J, Martin P, Coleman M, Furman RR. New Agents in Development for Non-Hodgkin's Lymphoma. Seminars in Hematology, 2007;44S18-S21
Coleman M, MartinP, Ruan J, Furman RR, Niesvisky R, Elstrom R, Lee C, George P, Leonard JP, Kaufman T. Lose Dose Metronomic, Multidrug Therapy with the PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Mantle Cell Lymphoma. Leukemia and Lymphoma, 2008;49(3):447-50
Coleman M, MartinP, Ruan J, Furman RR, Niesvisky R, Elstrom R, George P, Kaufman TP, Leonard JP. The PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Relapsing/Refractory Lymphoma: Low Dose Metronomic, Multidrug Therapy. Cancer, 2008;112(10):2228-2232 PMID 18338745
Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP. Novel and Engineered Anti-B cell Monoclonal Antibodies for Non-Hodgkin Lymphoma. Seminars in Hematology, 2008;45(2):126-132 PMID 18381108
Rutherford S, Andemariam B, Philips S, Elstrom R, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey T, Coleman M, Goldsmith S, Leonard JP. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia and Lymphoma, 2008;49(4):719-26 PMID 18398739
Martin P, Chadburn A, Christos P, Furman RR, Ruan J, Joyce M, Glynn P, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles D, Chen-Kiang S, Coleman M, Leonard JP. Intensive Treatment Strategies May Not Provide Superior Outcomes in Mantle Cell Lymphoma: Overall Survival Exceeding Seven Years with Conservative Therapies. Ann Oncol, 2008;19:1327-1330
Leonard JP, Martin P, Ruan J, Elstrom R, Barrientos J, Coleman M, Furman RR. New monoclonal antibodies for non-Hodgkin's lymphoma. Ann Oncol, 2008; 19(Suppl 4):iv60-iv62
Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol, 2008; 45(suppl 2):S1-S16 PMID 18760704
Estrom R, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematology/Oncology Clinics of North America, 2008;22(5):1037-1049 PMID 18954750
Czuchlewski D, Csernus B, Bubman D, Hyjek E, Martin P, Chadburn A, Knowles DM, Cesarman E. Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome. Am J Clin Pathol, 2008;130(6):957-62
Martin P, Coleman M, Leonard JP. Progress in Mantle Cell Lymphoma. J Clin Oncol, 2009; 27(4):481-483 PMID 19075257
Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, DiLiberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle cell lymphoma. J Clin Oncol, 2009;27(8):1209-13 PMID 19188674
Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzamab: A Promising New Agent for the Treatment of Lymphoid Malignancies. Expert Opin Investigational Drugs, 2009;18(1):99-104 PMID 19053886
Martin P, Leonard J, Furman R. Durable complete remissions in HIV-associated Hodgkin Lymphoma following treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma, 2009;9(3):247-9 PMID 19525196
Martin, P. Is there a role for bone scan for Hodgkin lymphoma in the age of FDG-PET? Leukemia and Lymphoma, 2009;50(11):1731-1732
Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L, Lee FY, Knowles DM, Coleman M, Wang L. Activity of SYK and PLC2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib. Clin Cancer Res, 2010;16(2):587-599 PMID 20068106
Elstrom R, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP. Response to second line therapy defines potential for cure in patients with recurrent diffuse large B cell lymphoma (DLBCL): Implications for development of novel therapeutic strategies. Clin Lymphoma Myeloma, 2010;10(3):192-196 PMID 20511164
Link B, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 tositumomab in patients with untreated low-grade follicular lymphoma: eight year follow-up of a multicenter phase II study. J Clin Oncol, 2010; 28(18):3035-3041 PMID 20458031
Martin P. When 18-fluorodeoxyglucose-positron emission tomography is indeterminate, the International Prognostic Index is the answer. Leukemia and Lymphoma, 2010;51(4):569-570
Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer, 2010;116(11):2655-2664 PMID 20235190
Thompson CA, Charlson ME, Schenkein E, Wells MT, Furman RR, Elstrom R, Ruan J, Martin P, Leonard JP. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010;21(11):2262-2266
Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom RE, Coleman M, Leonard JP. Phase I trial of bortezomib plus R-CHOP in previously untreated aggressive non-Hodgkin lymphoma. Cancer 2010;116(23):5432-5439 PMID 20665890
Leonard JP, Martin P. Novel agents for follicular lymphoma. Hematology 2010;2010:259-264 PMID 21239803
Ruan J, Martin P, Furman RR, Lee SH, Cheung K, Vose JM, LaCasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesaman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). J Clin Oncol 2011;29(6):690-697 PMID 21189393
Martin P, Leonard JP. Advancing through maintenance in mantle cell lymphoma. Leukemia and Lymphoma 2011;52(9)1617-1618 PMID 21699376
Martin P, Leonard JP. Is there a role for "watch and wait" in patients with mantle cell lymphoma? Seminars in Hematology 2011;48(3):189-193 PMID:21782061
Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RF, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, Gergis U. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Submitted
Bennani-Baiti N, Daw H, Cotta C, Martin P, Mitchell KW, Ambinder RF, Macklis R, Pollock R, Spiro T. Low grade follicular lymphoma of the small intestine. A challenge for management. Seminars in Oncology. 2011;38(6):714-720 PMID:22082756
Lee SM, Hershman DL, Martin P, Leonard JP, Cheung YK. Toxicity burden score: a novel approach to summarize multiple toxic effects. Ann Oncol 2012;23(2):537-541 PMID 21536663
Martin P. CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1: biomarkers in search of validation in lymphomas. Leuk Lymphoma. 2012;53(1):1-2 PMID:22035419
Leonard JP, LaCasce AS, Smith M, Noy A, Chireac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Larson SM, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK 4/6 inhibition and tumor responses are induced by PD0332991 in patients with mantle cell lymphoma. Blood. Accepted.
